⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Osel Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Osel Inc.
↗Mountain View, USA
Osel Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, that pioneers the development and commercialization of Live Biotherapeutic Products (LBPs). The company focuses on modulating the human microbiome to prevent or treat major medical conditions, with a primary emphasis on women's health and oncology.
Osel is recognized as a pioneer in the LBP field, having received one of the first FDA authorizations to test a live bacterial therapeutic in 2003. Its proprietary approach involves repopulating disrupted microbiomes with beneficial bacteria to restore health, targeting indications such as recurrent bacterial vaginosis, preterm birth prevention, and enhancing immunotherapy efficacy in cancer patients.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Live Biotherapeutic Products (LBPs)
Active Trials:6
Trial Phases:Phase 1: 1 | Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:SWOG Cancer Research Network (Phase 3 trial for MO-03), City of Hope (Oncology research), Imperial College London (FLIP-2 trial), March of Dimes (FLIP-2 trial), Miyarisan Pharmaceutical Co., Ltd. (Licensing of CBM588)
COMPETITION
Position:Niche Player
Competitors:Finch Therapeutics, Rebiotix, Evelo Biosciences
LEADERSHIP
Key Executives:
Peter P. Lee - Founder and Executive Chairman
Scientific Founders:Peter P. Lee
Board Members:Sandy Chau
LINKS
Website:oselinc.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Osel Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.